| 20-1119 |
Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al. |
Federal Circuit |
2021-02-16 |
Denied |
Amici (3)Response RequestedResponse WaivedRelisted (2) |
35-usc-103 graham-factors graham-v-john-deere hindsight-bias innovation innovation-protection nonobviousness-indicia objective-indicia obviousness-standard patent patent-law |
Whether a court must consider objective indicia of nonobviousness together with the other factors bearing on an obviousness challenge before making an… |
| 20-158 |
SRAM, LLC v. FOX Factory, Inc. |
Federal Circuit |
2020-08-13 |
Denied |
Response Waived |
35-usc-103 commercial-success federal-circuit graham-v-john-deere nonobviousness objective-indicia patent-act patent-claim patent-law person-of-ordinary-skill secondary-considerations statutory-interpretation |
In Graham v. John Deere Co. of Kansas City, 383 U.S. 1 (1966), this Court recognized the pivotal importance of "objective indicia" of nonobviousness (… |
| 18-1289 |
Allergan, Inc., et al. v. Teva Pharmaceuticals USA, Inc., et al. |
Federal Circuit |
2019-04-10 |
Denied |
Response Waived |
blocking-patent blocking-patent-doctrine commercial-success graham-v-john-deere long-felt-need objective-indicia objective-indicia-of-non-obviousness obviousness patent-law patent-law-doctrine-of-obviousness prior-art |
Whether the Federal Circuit erred in this case, as
it did in Acorda Therapeutics, Inc. v. Roxanne Laboratories, Inc., 903 F.3d 1310 (Fed. Cir. 2018), … |
| 18-1280 |
Acorda Therapeutics, Inc. v. Roxane Laboratories, Inc., et al. |
Federal Circuit |
2019-04-08 |
Denied |
Amici (5) |
blocking-patent-doctrine blocking-patents burden-of-proof graham-v-john-deere nonobviousness objective-indicia obviousness patent patent-law patent-obviousness pharmaceutical-innovation prior-art |
Under 35 U.S.C. § 103, a patent "may not be obtained . .. if the differences between the claimed invention and the prior art are such that the claimed… |